Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) has received a consensus recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $6.25.

Several research analysts have issued reports on CPRX shares. Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, August 10th. SunTrust Banks reiterated a “buy” rating and set a $5.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Tuesday, September 5th. Zacks Investment Research lowered Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, October 11th. HC Wainwright reiterated a “buy” rating and set a $6.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Friday, November 10th. Finally, Piper Jaffray Companies set a $8.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a research note on Friday, December 1st.

Several large investors have recently made changes to their positions in the company. Geode Capital Management LLC increased its stake in shares of Catalyst Pharmaceuticals by 0.3% in the first quarter. Geode Capital Management LLC now owns 462,677 shares of the biopharmaceutical company’s stock valued at $902,000 after buying an additional 1,446 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Catalyst Pharmaceuticals by 3.6% in the first quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock valued at $135,000 after buying an additional 2,404 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Catalyst Pharmaceuticals by 0.5% in the first quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock valued at $5,865,000 after buying an additional 15,600 shares in the last quarter. OxFORD Asset Management LLP increased its stake in shares of Catalyst Pharmaceuticals by 46.2% in the second quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock valued at $238,000 after buying an additional 27,228 shares in the last quarter. Finally, Nationwide Fund Advisors acquired a new stake in shares of Catalyst Pharmaceuticals in the second quarter valued at $111,000. Institutional investors own 35.57% of the company’s stock.

Catalyst Pharmaceuticals (NASDAQ CPRX) opened at $4.01 on Thursday. Catalyst Pharmaceuticals has a 12 month low of $1.01 and a 12 month high of $4.51.

ILLEGAL ACTIVITY NOTICE: “Catalyst Pharmaceuticals Inc (CPRX) Receives Average Rating of “Buy” from Analysts” was originally reported by American Banking News and is the sole property of of American Banking News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://www.americanbankingnews.com/2017/12/07/catalyst-pharmaceuticals-inc-cprx-receives-average-rating-of-buy-from-analysts.html.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Receive News & Ratings for Catalyst Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.